Loading...
Please wait, while we are loading the content...
OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia
| Content Provider | Scilit |
|---|---|
| Author | Advani, Anjali S. Lim, Kathleen Gibson, Sarah Shadman, Mazyar Jin, Tao Copelan, Ed Kalaycio, Matt Sekeres, Mikkael A. Sobecks, Ronald Hsi, Eric |
| Copyright Year | 2010 |
| Description | OCT-2 and its co-activator, BOB.1, are B-cell associated transcription factors expressed in a subset of patients with acute myeloid leukemia (AML). We evaluated OCT-2 and BOB.1 expression by immunohistochemistry in patients with newly diagnosed AML. The median overall survival (OS) for patients with varying levels of OCT-2 expression was statistically different (p = 0.03) (OCT-2 50%: 11.6 months). On multivariate analysis, co-expression of OCT-2/BOB.1 remained predictive for achievement of complete remission (HR 0.44, p = 0.010) and increased risk of relapse (HR 2.30, p = 0.047). OCT-2 (per 10% increase) was associated with a decreased progression-free survival (HR 1.10, p = 0.036) and a trend toward a worse OS (HR 1.10, p = 0.063). OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2. These results will need to be validated prospectively. |
| Related Links | http://www.tandfonline.com/doi/pdf/10.3109/10428191003592735 |
| Ending Page | 612 |
| Page Count | 7 |
| Starting Page | 606 |
| ISSN | 10428194 |
| e-ISSN | 10292403 |
| DOI | 10.3109/10428191003592735 |
| Journal | Leukemia & Lymphoma |
| Issue Number | 4 |
| Volume Number | 51 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2010-04-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Leukemia & Lymphoma Hematology Medical Laboratory Technology Acute Myeloid Leukemia Prognosis Expression Oct-2 Bob.1 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology Cancer Research Oncology |
